Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 3, 2015. The report disseminates a press release from ViiV Healthcare, a global specialist HIV company in which GSK is a shareholder alongside Pfizer Inc. and Shionogi Limited. The filing focuses on clinical trial results rather than GSK's consolidated financial performance.
Key Financial Metrics
The filing text does not provide a clear value for GSK's revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a specific clinical milestone for a joint venture and does not contain financial statements or key performance indicators for the parent company.
Material Changes and Clinical Results
The primary material event is the announcement of positive headline results from the Phase IIb LATTE 2 study (NCT02120352) regarding a long-acting injectable HIV maintenance regimen. Key findings include:
- Primary Endpoint Met: The study met its primary endpoint at 32 weeks, showing that investigational long-acting injectable formulations of cabotegravir and rilpivirine were comparable to a three-drug oral regimen in maintaining viral suppression.
- Viral Suppression Rates: Patients receiving injections every 8 weeks (Q8W) achieved a 95% suppression rate, while those receiving injections every 4 weeks (Q4W) achieved 94%. The oral control group achieved 91%.
- Study Design: The study involved 309 adults who had previously achieved viral suppression on oral therapy and were randomized into three arms: Q4W injections, Q8W injections, or continued oral therapy.
Outlook, Risks, and Management Commentary
Management Commentary: John C. Pottage, Jr., MD, Chief Scientific and Medical Officer at ViiV Healthcare, stated that the data is promising and builds on previous results, with the company looking forward to Phase III trials.
Risks and Adverse Events:
- Injection Site Pain: This was the most common adverse event, reported by 93% of injection recipients.
- Withdrawal Rates: Patients switching to the Q4W injection regimen reported more adverse events leading to withdrawal (5%) compared to the Q8W regimen (2%) or the oral regimen (2%).
- Intolerance: Two patients in the Q8W arm withdrew due to injection intolerance.
- Virologic Failure: Two patients met failure criteria (one in Q8W, one in oral), with no evidence of resistance at failure.
Outlook: The 32-week results are scheduled for presentation at a forthcoming scientific conference. The company is committed to moving into Phase III trials.
Investor Verification Checklist
- Verify the timeline and enrollment criteria for the upcoming Phase III trials of cabotegravir and rilpivirine.
- Monitor the presentation of the full 32-week LATTE 2 data at the forthcoming scientific conference.
- Assess the long-term safety profile regarding injection site pain and patient adherence to the Q4W versus Q8W dosing schedules.
- Review GSK's ownership stake and profit-sharing agreement with ViiV Healthcare to understand the financial impact of future drug approvals.